Table 1.
Baseline demographic and clinical characteristics of patients treated with monoclonal antibodies (MAB) and pegylated (PEG) TNFi.
| Total n = 170 | MAB n = 138 | PEG n = 32 | p | |
|---|---|---|---|---|
| Sociodemographic characteristics | ||||
| Female sex, n (%) | 141 (83%) | 115 (83%) | 26 (81%) | 0.778 |
| Age (years), median (IQR) | 56.0 (45.8–66.1) | 55.0 (44.8–65.0) | 59.7 (47.7–70.1) | 0.070 |
| BMI, median (IQR) | 24.6 (21.8–29.1) | 24.3 (21.6–28.7) | 24.7 (22.6–30.5) | 0.561 |
| Smoking status | n = 164 | n = 136 | n = 28 | 0.099 |
|
27 (17%) | 22 (16%) | 5 (18%) | |
|
40 (24%) | 29 (21%) | 11 (39%) | |
|
97 (59%) | 85 (63%) | 12 (43%) | |
| Disease duration, (years) | 8.5 (4.3–14.3) | 8.5 (4.2–14.4) | 8.9 (4.4–11.4) | 0.921 |
| Serological characteristics | ||||
| CRP mg/L, Median (IQR) | 7.5 (3.0–21.4) | 7.8 (3.0–22.8) | 12.8 (2.4–17.6) | 0.734 |
| RF status (n, %) | 128 (75%) | 103 (75%) | 25 (78%) | 0.680 |
| RF levels (n, %) | ||||
| Low: <203 IU/mL | 117 (69%) | 95 (69%) | 22 (69%) | 0.992 |
| High: ≥203 IU/mL | 53 (31%) | 43 (31%) | 10 (31.3%) | |
| ACPA status, (n/N, %) | 135/168 (80%) | 108/136 (79%) | 27/32 (84%) | 0.525 |
| Clinical characteristics | ||||
| DAS28, mean ± SD | 5.06 ± 1.35 | 5.08 ± 1.36 | 4.97 ± 1.33 | 0.480 |
| Treatment characteristics | ||||
| Previous bDMARD use, n (%) | 26 (15%) | 20 (15%) | 6 (19%) | 0.547 |
| Monotherapy, n (%) | 16 (10%) | 16 (12%) | 0 (0%) | 0.042 |
| MTX use, n (%) | 113 (67%) | 96 (70%) | 17 (53%) | 0.067 |
| Other DMARDs use, n (%) | 40 (23%) | 25 (18%) | 15 (47%) | 0.001 |
| Prednisone use, n (%) | 85 (50%) | 69 (50%) | 16 (50%) | 0.970 |
RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; BMI, body mass index; DAS28, 28-joint Disease Activity Score 28; CRP, C-reactive protein; bDMARD, biologic disease-modifying drug; MTX, methotrexate.